Molecular profile
Molecular profile
- Molecule class
- Peptide analogue
- Origin
- Synthetic analogue
- Primary target system
- GIP- und GLP-1-Rezeptoren
- Development stage
- Authorised active substance
Langwirksames, acyliertes duales GIP/GLP-1-Rezeptoragonisten-Peptid.
Mechanism and signalling
Mechanism and signalling
Combined incretin-receptor activation affects glucose-dependent endocrine signals, food intake and metabolic regulation.
Scientific classification
Scientific classification
This profile maps Tirzepatid to the research areas metabolism, endocrine. Molecule class, evidence level, development stage and regulatory status are separated so that preclinical findings are not confused with authorised uses.
Pathways related to glucose homeostasis, appetite, energy expenditure and body composition.
Peptide hormones and analogues related to hypothalamic, pituitary and peripheral endocrine systems.
Evidence base
Approval and post-marketing data
Large phase III programmes and regulatory assessments are available. Conclusions apply only to authorised products and the populations studied.
Regulatory status
Authorised in the EU/multiple markets
The active substance is used in authorised medicines in multiple jurisdictions. Authorisations apply only to defined products, indications, quality standards and conditions of use.
Safety and use notice
No dosing or administration recommendation
The available evidence does not establish safe self-directed use. This profile intentionally provides no dosing, sourcing or administration guidance.
Sources and registries